Sep 12, 2023 / 12:00PM GMT
Operator
Good afternoon, and welcome to the Humacyte data call. (Operator Instructions) At this time, I would now like to turn the call over to your host, Laura Niklason, Chief Executive Officer of Humacyte. Please go ahead, Laura.
Laura E. Niklason - Humacyte, Inc. - Founder, President, CEO & Director
Thank you, Sarah, and welcome, everyone, to our top line results and KOL webinar call regarding our CLN-PRO-V005 trial of the HAV in vascular trauma. This is Humacyte's typical disclaimers regarding forward-looking statements. Just as a reminder to those on the call, Humacyte really leads the field of regenerative medicine in the bioengineering of tissues and organs. Our human acellular vessel or HAV is available off the shelf and is universally implantable with no immunosuppression.
In addition, we've observed that the HAV repopulates with cells from the patient over time after implantation, becoming a living tissue. We believe this is category-defining innovation that creates new tissues for patients with a variety of medical conditions. If we look now at
Humacyte Inc Top Line Data Announcement Transcript
Sep 12, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers